Fractal calculus in tumor growth simulations: The proof is in the pudding.

Fractal calculus Mathematical modeling Oncology Predictive model

Journal

Bio Systems
ISSN: 1872-8324
Titre abrégé: Biosystems
Pays: Ireland
ID NLM: 0430773

Informations de publication

Date de publication:
Mar 2024
Historique:
received: 08 01 2024
revised: 05 02 2024
accepted: 06 02 2024
medline: 18 3 2024
pubmed: 15 2 2024
entrez: 14 2 2024
Statut: ppublish

Résumé

Mathematical modeling in oncology has a long history. Recently, mathematical models and their predictions have made inroads into prospective clinical trials with encouraging results. The goal of many such modeling efforts is to make predictions, either to clinician's choice therapy or into "optimal" therapy - often for individual patients. The mathematical oncology community rightfully puts great hope into predictive modeling and mechanistic digital twins - but with this great opportunity comes great responsibility. Mathematical models need to be rigorously calibrated and validated, and their predictive performance ascertained, before conclusions about predictions into the unknown can be drawn. The recent article "Modeling tumor growth using fractal calculus: Insights into tumor dynamics" (Golmankhaneh et al., 2023), applied fractal calculus to tumor growth data. In this short commentary, I raise concerns about the study design and interpretation. In its current form, this study is poised to put cancer patients at risk if interpreted as concluded by the authors.

Identifiants

pubmed: 38355079
pii: S0303-2647(24)00026-1
doi: 10.1016/j.biosystems.2024.105141
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

105141

Informations de copyright

Copyright © 2024 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest I declare no conflict of interest.

Auteurs

Heiko Enderling (H)

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Institute for Data Science in Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: henderling@mdanderson.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH